Canada markets closed

Provention Bio, Inc. (2VB.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
8.67+0.16 (+1.90%)
At close: 09:15AM CET
Full screen
Previous Close8.50
Open8.67
Bid8.81 x 0
Ask9.17 x 0
Day's Range8.67 - 8.67
52 Week Range3.20 - 9.25
Volume2,000
Avg. Volume274
Market Cap779.31M
Beta (5Y Monthly)2.36
PE Ratio (TTM)N/A
EPS (TTM)-1.56
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.79
  • Motley Fool

    Is This Biotech Stock a Buy Following a Landmark Approval?

    Provention Bio (NASDAQ: PRVB) is a small-cap biotech whose shares have doubled in the past three months. The company can thank the expected and eventual approval of Tzield for that performance. In mid-November, Tzield became the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for the delay of the onset of type 1 diabetes (T1D) in at-risk patients.

  • Zacks

    Provention (PRVB) Gets FDA Nod for Drug That Delays T1D Onset

    Following FDA approval, Provention Bio's (PRVB) Tzield is the first disease-modifying therapy in T1D. Tzield can delay the onset of stage 3 T1D in individuals aged eight years and older.

  • Reuters

    UPDATE 1-Provention Bio diabetes drug to cost $13,850/vial

    Provention Bio Inc said on Friday its recently approved diabetes drug, teplizumab, would cost $13,850 a vial. The U.S. Food and Drug Administration approved use of the drug, to be sold under brand name Tzield, late on Thursday for delaying the onset of insulin-dependent type 1 diabetes, which is less common than type 2 of the disease, for people aged 8 years and above. In October, Provention signed a co-promotion deal for the drug with Sanofi, offering the French drugmaker first negotiation for exclusive global rights to commercialize the drug in exchange for an upfront payment of $20 million.